Regeneron Pharmaceuticals Inc. has been riding the wave of profits from its drug to treat a leading cause of adult blindness. Revenue recently spiked 45 percent in part because the drug, called Eylea, expanded into markets outside the U.S.

Regeneron Pharmaceuticals Inc. has been riding the wave of profits from its drug to treat a leading cause of adult blindness. Revenue recently spiked 45 percent in part because the drug, called Eylea, expanded into markets outside the U.S.

Dr. Michael Aberman, chief strategy officer of Regeneron, on Tuesday said the company remains on track to nearly double its employee total during the next five years, reaching up to 5,000.

But that goal involves making more than just one highly profitable drug, a strategy well underway at the public company headquartered in Tarrytown, New York.
Three other Regeneron drugs are poised to hit markets to treat skin diseases, high cholesterol and arthritis. They are expected to play a major role in the job creation. The new drugs also have helped boost the public company’s stock prices.

“It’s something that really differentiates us because coming to market with a blockbuster drug, often times you’re scrambling to come up with what’s next,” Aberman said.
Regeneron has yet to disclose where the hiring would take place. Candidates include the company’s East Greenbush manufacturing facility, just outside Albany, where the employee count has recently increased from 600 to 900

David Robinson